BACKGROUND: CDKN2A mutations confer a substantial risk of cutaneous melanoma; however, the magnitude of risk is uncertain. METHODS: The study estimated the hazard ratio (HR) and the average age specific cumulative risk (ie, penetrance) of reported melanoma for CDKN2A mutation carriers in case families using a modified segregation analysis of the first and higher degree relatives of 35 population-based cases. The study sample included 223 relatives of 13 melanoma cases diagnosed when aged 18-39 years from Melbourne, Sydney and Brisbane, Australia, and 322 relatives of 22 melanoma cases diagnosed at any age from Yorkshire, UK. RESULTS: The estimated HR for melanoma for mutation carriers relative to the general population decreased with regions of increasing ambient ultraviolet (UV) irradiance, being higher for the UK than Australia (87, 95% CI 50 to 153 vs 31, 95% CI 20 to 50, p=0.008), and across Australia, 49 (95% CI 24 to 98) for Melbourne, 44 (95% CI 22 to 88) for Sydney, and 9 (95% CI 2 to 33) for Brisbane (p=0.02). Penetrance did not differ by geographic region. It is estimated that 16% (95% CI 10% to 27%) of UK and 20% (95% CI 13% to 30%) of Australian CDKN2A mutation carriers would be diagnosed with melanoma by age 50 years, and 45% (95% CI 29% to 65%) and 52% (95% CI 37% to 69%), respectively, by age 80 years. CONCLUSIONS: Contrary to the strong association between UV radiation exposure and melanoma risk for the general population, CDKN2A mutation carriers appear to have the same cumulative risk of melanoma irrespective of the ambient UV irradiance of the region in which they live.
BACKGROUND: CDKN2A mutations confer a substantial risk of cutaneous melanoma; however, the magnitude of risk is uncertain. METHODS: The study estimated the hazard ratio (HR) and the average age specific cumulative risk (ie, penetrance) of reported melanoma for CDKN2A mutation carriers in case families using a modified segregation analysis of the first and higher degree relatives of 35 population-based cases. The study sample included 223 relatives of 13 melanoma cases diagnosed when aged 18-39 years from Melbourne, Sydney and Brisbane, Australia, and 322 relatives of 22 melanoma cases diagnosed at any age from Yorkshire, UK. RESULTS: The estimated HR for melanoma for mutation carriers relative to the general population decreased with regions of increasing ambient ultraviolet (UV) irradiance, being higher for the UK than Australia (87, 95% CI 50 to 153 vs 31, 95% CI 20 to 50, p=0.008), and across Australia, 49 (95% CI 24 to 98) for Melbourne, 44 (95% CI 22 to 88) for Sydney, and 9 (95% CI 2 to 33) for Brisbane (p=0.02). Penetrance did not differ by geographic region. It is estimated that 16% (95% CI 10% to 27%) of UK and 20% (95% CI 13% to 30%) of Australian CDKN2A mutation carriers would be diagnosed with melanoma by age 50 years, and 45% (95% CI 29% to 65%) and 52% (95% CI 37% to 69%), respectively, by age 80 years. CONCLUSIONS: Contrary to the strong association between UV radiation exposure and melanoma risk for the general population, CDKN2A mutation carriers appear to have the same cumulative risk of melanoma irrespective of the ambient UV irradiance of the region in which they live.
Authors: A Antoniou; P D P Pharoah; S Narod; H A Risch; J E Eyfjord; J L Hopper; N Loman; H Olsson; O Johannsson; A Borg; B Pasini; P Radice; S Manoukian; D M Eccles; N Tang; E Olah; H Anton-Culver; E Warner; J Lubinski; J Gronwald; B Gorski; H Tulinius; S Thorlacius; H Eerola; H Nevanlinna; K Syrjäkoski; O-P Kallioniemi; D Thompson; C Evans; J Peto; F Lalloo; D G Evans; D F Easton Journal: Am J Hum Genet Date: 2003-04-03 Impact factor: 11.025
Authors: Colin B Begg; Irene Orlow; Amanda J Hummer; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Stephen B Gruber; Hoda Anton-Culver; Roberto Zanetti; Richard P Gallagher; Terence Dwyer; Timothy R Rebbeck; Nandita Mitra; Klaus Busam; Lynn From; Marianne Berwick Journal: J Natl Cancer Inst Date: 2005-10-19 Impact factor: 13.506
Authors: Clare L Scott; Mark A Jenkins; Melissa C Southey; Tracey A Davis; Jennifer A Leary; Douglas F Easton; Kelly-Anne Phillips; John L Hopper Journal: Hum Genet Date: 2003-02-25 Impact factor: 4.132
Authors: F Demenais; H Mohamdi; V Chaudru; A M Goldstein; J A Newton Bishop; D T Bishop; P A Kanetsky; N K Hayward; E Gillanders; D E Elder; M F Avril; E Azizi; P van Belle; W Bergman; G Bianchi-Scarrà; B Bressac-de Paillerets; D Calista; C Carrera; J Hansson; M Harland; D Hogg; V Höiom; E A Holland; C Ingvar; M T Landi; J M Lang; R M Mackie; G J Mann; M E Ming; C J Njauw; H Olsson; J Palmer; L Pastorino; S Puig; J Randerson-Moor; M Stark; H Tsao; M A Tucker; P van der Velden; X R Yang; N Gruis Journal: J Natl Cancer Inst Date: 2010-09-28 Impact factor: 13.506
Authors: Juliette A Randerson-Moor; John C Taylor; Faye Elliott; Yu-Mei Chang; Samantha Beswick; Kairen Kukalizch; Paul Affleck; Susan Leake; Sue Haynes; Birute Karpavicius; Jerry Marsden; Edwina Gerry; Linda Bale; Chandra Bertram; Helen Field; Julian H Barth; Isabel Dos Santos Silva; Anthony Swerdlow; Peter A Kanetsky; Jennifer H Barrett; D Timothy Bishop; Julia A Newton Bishop Journal: Eur J Cancer Date: 2009-07-15 Impact factor: 9.162
Authors: D Timothy Bishop; Florence Demenais; Alisa M Goldstein; Wilma Bergman; Julia Newton Bishop; Brigitte Bressac-de Paillerets; Agnès Chompret; Paola Ghiorzo; Nelleke Gruis; Johan Hansson; Mark Harland; Nicholas Hayward; Elizabeth A Holland; Graham J Mann; Michela Mantelli; Derek Nancarrow; Anton Platz; Margaret A Tucker Journal: J Natl Cancer Inst Date: 2002-06-19 Impact factor: 13.506
Authors: Mark Harland; Alisa M Goldstein; Kairen Kukalizch; Claire Taylor; David Hogg; Susana Puig; Celia Badenas; Nelleke Gruis; Jeanet ter Huurne; Wilma Bergman; Nicholas K Hayward; Mitchell Stark; Hensin Tsao; Margaret A Tucker; Maria Teresa Landi; Giovanna Bianchi Scarra; Paola Ghiorzo; Peter A Kanetsky; David Elder; Graham J Mann; Elizabeth A Holland; D Timothy Bishop; Julia Newton Bishop Journal: Eur J Cancer Date: 2008-04-03 Impact factor: 9.162
Authors: Bhramar Mukherjee; John Oliver Delancey; Leon Raskin; Jessica Everett; Joanne Jeter; Colin B Begg; Irene Orlow; Marianne Berwick; Bruce K Armstrong; Anne Kricker; Loraine D Marrett; Robert C Millikan; Hoda Anton Culver; Stefano Rosso; Roberto Zanetti; Peter A Kanetsky; Lynn From; Stephen B Gruber Journal: J Natl Cancer Inst Date: 2012-04-24 Impact factor: 13.506
Authors: Margaret A Tucker; David E Elder; Michael Curry; Mary C Fraser; Virginia Pichler; Deborah Zametkin; Xiaohong R Yang; Alisa M Goldstein Journal: J Invest Dermatol Date: 2018-02-08 Impact factor: 8.551
Authors: Jennifer M Taber; Lisa G Aspinwall; Danielle M Drummond; Tammy K Stump; Wendy Kohlmann; Marjan Champine; Pamela Cassidy; Sancy A Leachman Journal: Ann Behav Med Date: 2021-02-12
Authors: Marianne Berwick; Colin B Begg; Bruce K Armstrong; Anne S Reiner; Nancy E Thomas; Linda S Cook; Irene Orlow; Anne Kricker; Loraine D Marrett; Stephen B Gruber; Hoda Anton-Culver; Robert C Millikan; Richard P Gallagher; Terry Dwyer; Stefano Rosso; Peter A Kanetsky; Julia Lee-Taylor Journal: J Invest Dermatol Date: 2011-08-11 Impact factor: 8.551
Authors: Mark Harland; Anne E Cust; Celia Badenas; Yu-Mei Chang; Elizabeth A Holland; Paula Aguilera; Joanne F Aitken; Bruce K Armstrong; Jennifer H Barrett; Cristina Carrera; May Chan; Joanne Gascoyne; Graham G Giles; Chantelle Agha-Hamilton; John L Hopper; Mark A Jenkins; Peter A Kanetsky; Richard F Kefford; Isabel Kolm; Johanna Lowery; Josep Malvehy; Zighereda Ogbah; Joan-Anton Puig-Butille; Jordi Orihuela-Segalés; Juliette A Randerson-Moor; Helen Schmid; Claire F Taylor; Linda Whitaker; D Timothy Bishop; Graham J Mann; Julia A Newton-Bishop; Susana Puig Journal: Hered Cancer Clin Pract Date: 2014-11-20 Impact factor: 2.857